Roche’s Foundation Medicine will expand its cancer monitoring portfolio by acquiring SAGA Diagnostics for up to $595 million including milestone payments. The transaction is expected to close by the third quarter of 2026, subject to regulatory approvals. SAGA’s Pathlight platform combines whole genome sequencing and digital PCR to detect and track structural variants for ultra-sensitive MRD monitoring. Foundation said Pathlight is covered by Medicare for monitoring recurrence in early-stage breast cancer, and it plans to broaden access internationally. The companies also discussed plans to pair Pathlight with Roche’s AXELIOS sequencing platform and Digital LightCycler PCR systems to develop a decentralized MRD solution, targeting wider availability beyond specialty centers. The move highlights continued consolidation in MRD diagnostics as demand grows for clinically action-ready monitoring tools.